T19	Exp 149 163	our laboratory
T20	Exp 175 179	that
T21	Exp 180 199	the earliest stages
T22	Exp 300 316	The interactions
T23	Exp 536 538	it
T24	Exp 549 553	that
T25	Exp 716 724	the risk
T26	Exp 758 788	These conflicting observations
T27	Exp 954 956	we
T28	Exp 935 952	the present study
T29	Exp 966 977	the effects
T30	Exp 1076 1090	the expression
T31	Exp 1265 1286	the activation status
T32	Exp 1290 1315	the transcription factors
T33	Exp 1451 1464	the exception
T34	Exp 1482 1508	the used immunosuppressive
T35	Exp 1868 1882	the modulation
T36	Exp 1833 1851	These observations
T37	Exp 2069 2073	that
T38	Exp 2131 2142	Our results
T39	Exp 2148 2152	that
T40	Exp 2261 2265	that
T41	Exp 2338 2342	that
T42	Exp 2153 2170	the tested agents
T43	Exp 2211 2216	the T
T44	Exp 2656 2669	its potential
T45	Exp 2708 2721	its inability
T46	Exp 2442 2446	that
T47	Exp 2585 2589	that
T48	Exp 2783 2787	that
T49	Exp 2407 2426	the molecular basis
T50	Exp 2431 2441	the notion
T51	Exp 2459 2486	the anti-atherogenic effect
T52	Exp 2512 2526	the prevention
T53	Exp 2530 2542	the adhesion
T54	Exp 2598 2634	the atherosclerosis-promoting effect
T55	Exp 2889 2908	the arterial intima
T56	Exp 2388 2398	These data
R5	Coref Anaphora:T37 Antecedent:T57
R6	Coref Anaphora:T46 Antecedent:T50
R7	Coref Anaphora:T44 Antecedent:T58
R8	Coref Anaphora:T45 Antecedent:T59
T1	Protein 269 290	heat shock protein 60
T2	Protein 292 297	Hsp60
T3	Protein 320 325	Hsp60
T4	Protein 407 412	Hsp60
T5	Protein 1114 1148	monocyte chemoattractant protein-1
T6	Protein 1150 1155	MCP-1
T7	Protein 1162 1167	Hsp60
T8	Protein 1354 1373	heat shock factor-1
T9	Protein 1375 1380	HSF-1
T10	Protein 1703 1730	tumor necrosis factor-alpha
T11	Protein 1732 1741	TNF-alpha
T12	Protein 1952 1957	Hsp60
T13	Protein 2042 2047	Hsp70
T14	Protein 2103 2108	HSF-1
T15	Protein 2371 2376	Hsp60
T16	Protein 2687 2692	Hsp60
T17	Protein 2807 2812	MCP-1
T57	Exp 2062 2068	HUVECs
T58	Exp 2590 2594	part
T59	Exp 2673 2683	an inducer
